IDSA against HCQ and Plasma

Two days ago, the Infectious Disease Society (IDSA) published its recommendations against the use of Hydroxychloroquine and convalescent plasma for the treatment of COVID-19. Apparently, they knew that Trump would announce the FDA authorization of plasma therapy for COVID-19, and they wanted to strike  preemptively. At the same time, they recommended the use of the ineffective and unsafe drug, Remdesivir.

IDSA justified its recommendation against HCQ by repeating earlier lies and fallacies. It disregarded  real-world evidence, and commingled  differing treatment regimens including HCQ into  one – as if all treatment regimens, time of administration and dosages were the same.They presented  a review that included already refuted failures and frauds (Magagnoli, Geleris, Mahevas, Rosenberg, etc.), and excluded large studies showing great effectiveness of Hydroxychloroquine + Azithromycin treatment. Here are just some of the excluded studies:

Lagier et al., Outcomes of 3,737 COVID-19 patients treated with Hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis, June 25, 2020

Yu et al., Beneficial effects exerted by hydroxychloroquine in treating COVID-19, August 3, 2020

Scholz, Derwand, Zelenko. COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxychloroquine and Azithromycin, preprint, July 3, 2020

Read The Lancet Doubles Down on anti-HCQ Fraud